Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TMP 301

Next Previous
X
Search
Drug Profile

TMP 301

Alternative Names: Heptares 25; HTL-0014242; HTL14242; TMP-301

Latest Information Update: 23 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sosei Heptares
  • Developer Nxera Pharma; Tempero Bio
  • Class Antipsychotics; Anxiolytics; Behavioural disorder therapies; Benzonitrile; Drug withdrawal therapies; Neuroprotectants; Nitriles; Pyrimidines; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cocaine-related disorders; Substance-related disorders
  • Discontinued Anxiety disorders; Neurological disorders; Psychiatric disorders

Most Recent Events

  • 18 Oct 2024 Tempero Bio plans a phase-II trial for Alcoholism in December 2024 (PO), (NCT06648655),
  • 18 Oct 2024 Tempero Bio plans to initiate a phase I trial for Cocaine-related disorders (PO) (NCT06648668)
  • 31 Mar 2024 Sosei Heptares is now called Nxera Pharma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top